バリントス・バイオセラピュ―ティクスのニュース一覧

12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga12/14 05:06

Barinthus Biotherapeutics Plc (NASDAQ:BRNS) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough

Simply Wall St11/26 19:10

Press Release: Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

Dow Jones11/26 05:01

European Equities Traded in the US as American Depositary Receipts Rising Monday

MT Newswires11/26 00:13

ADRs End Lower; Barinthus Biotherapeutics PLC Declines 30%

Dow Jones11/16 05:31

Barinthus Biotherapeutics Shares Are Trading Lower. The Company Announced Data From the Ongoing Phase 2b HBV003 Clinical Trial.

Benzinga11/16 02:19

Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results

MT Newswires11/16 01:27

Arbutus And Barinthus Bio Report IM-PROVE II Trial Data Showing Nivolumab Boosts HBsAg Loss Rates In Chronic Hepatitis B Patients; 23% Achieve HBsAg Loss By Week 48 With Imdusiran, VTP-300, And Low-Dose Nivolumab

Benzinga11/16 00:02

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

GlobeNewswire11/16 00:02

Barinthus Biotherapeutics Q3 EPS $(0.21) Beats $(0.44) Estimate, Sales $14.97M

Benzinga11/06 21:18

10-Q：Q3 2024 四半期報告書

SEC11/06 21:12

8-K：バリンサスバイオは、企業の動向と財務結果に関する2024年第3四半期の最新情報を報告しています

SEC11/06 21:07

Barinthus Biotherapeutics 3Q Rev $15M >BRNS

Dow Jones11/06 21:03

Barinthus Biotherapeutics 3Q Loss/Shr 21c >BRNS

Dow Jones11/06 21:03

Barinthus Biotherapeutics 3Q Loss $8.13M >BRNS

Dow Jones11/06 21:03

Press Release: Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Dow Jones11/06 21:00

Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting and Attendance at November Conferences

GlobeNewswire10/31 20:00

Barinthus Reports Completion Of Enrollment For Two Clinical Trials: HBV003 And PCA001

Benzinga10/01 20:02

H.C. Wainwrightはバリントス・バイオセラピュ―ティクス(BRNS.US)のレーティングを強気に据え置き、目標株価を5ドルに据え置いた

H.C. WainwrightのアナリストYi Chenは$Barinthus Biotherapeutics(BRNS.US)$のレーティングを強気に据え置き、目標株価を5ドルに据え置いた。TipRanksのデータによると、このアナリストの最近1年間の的中率は30.8%、平均リターンは-20.9%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに

Futuニュース09/26 00:31

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

GlobeNewswire09/24 20:00